

Dr Ruth Harvey

Publications

Harvey R, Johnson R, MacLellan-Gibson K, Robertson J and Engelhardt O. A promoter mutation in the HA segment of influenza A virus generates an effective candidate live attenuated vaccine. *Influenza and Other Respiratory Viruses*. (2014) *in press*

Johnson R.E., Hamill M., Harvey R., Nicolson C., Robertson J.S. and Engelhardt O.G. Permissible variation in the 3' non-coding region of the haemagglutinin genome segment of the H5N1 candidate influenza vaccine virus NIBRG-14. *PLoS One* **7**(2012) e36241.

Harvey R., Hamill M., Robertson J.S., Minor P.M. Vodeiko G.M., Weir J.P. Takahashi H., Harada Y., Itamura S., Bamford P., Dalla Pozza T. and Engelhardt O.G. Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards. *Biologicals* **40**(2012), 96-99.

Nicolson C., Harvey R., Johnson R., Guilfoyle K., Engelhardt O.G. and Robertson J.S. An additional oligosaccharide moiety on the HA of a pandemic influenza H1N1 candidate vaccine virus confers increased antigen yield in eggs. *Vaccine* **30**(2012), 745-751.

Harvey R., Guilfoyle K.A., Roseby S., Robertson J.S. and Engelhardt O.G. Improved Antigen Yield in Pandemic H1N1 (2009) Candidate Vaccine Viruses with Chimeric Hemagglutinin Molecules. *Journal of Virology* **85**(2011), 6086-6090

Robertson J.S., Nicolson C., Harvey R., Johnson R., Major D., Guilfoyle K., Roseby S., Newman R., Collin R., Wallis C., Engelhardt O.G., Wood J.M., Le J., Manojkumar R., Pokorny B.A., Silverman J., Devis R., Bucher D., Verity E., Agius C., Camuglia S., Ong C., Rockman S., Curtis A., Schoofs P., Zoueva O., Xie H., Li X., Lin Z., Ye Z., Chen L.M., O'Neill E., Balish A., Lipatov A.S., Guo Z., Isakova I., Davis C.T., Rivaller P., Gustin K.M., Belser J.A., Maines T.R., Tumpey T.M., Xu X., Katz J.M., Klimov A., Cox N.J., Donis R.O. 2011. The development of vaccine viruses against pandemic A(H1N1) influenza. *Vaccine* **29**(2011),1836-1843

Harvey R., Nicolson C., Johnson R.E., Guilfoyle K.A., Major D.L., Robertson J.S. and Engelhardt O.G. Improved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules. *Vaccine* **28**(2010), 8008–8014.

Harvey R., Wheeler J.X., Wallis C.L., Robertson J.S. and Engelhardt O.G. Quantitation of Haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). *Vaccine* **26**(2008), 6550 – 6554.

Harvey R. Martin, A.C.R., Zambon M. and Barclay W.S. Restrictions to the Adaptation of Influenza A Virus H5 Haemagglutinin to the Human Host. *Journal of Virology* **78**. (2004), 502-507.

Griffin S.D.C., Harvey R., Clarke D.S., Barclay W.S., Harris M. and Rowlands J.A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion-channel activity in mammalian cells but is dispensable for localization to mitochondria. *Journal of General Virology* **85**(2004), 451-461

Rowley K.V., Harvey R. and Barclay W.S. Isolation and characterisation of a transfectant influenza B virus altered in RNA segment 6. *Journal of General Virology* **80**(1999), 2353-2359.